Showing results (51-60 of 333) with videos related to

Sort By:
Pageof 34
Cancer Science|October 27, 2016
Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesotheliomaAkiko Harada, Junji Uchino, Taishi Harada, et al.
Medicine|June 8, 2018
Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasisKeiko Tanimura, Junji Uchino, Nobuyo Tamiya, et al.
Translational Lung Cancer Research|February 4, 2020
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancerYuki Katayama, Tadaaki Yamada, Takayuki Shimamoto, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|June 2, 2020
The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosisSaiko Ogata-Suetsugu, Naoki Hamada, Koichi Takayama, et al.
The Oncologist|July 24, 2019
Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung CancerKoichi Takayama, Masao Ichiki, Shoji Tokunaga, et al.
Cancer Treatment Reviews|October 10, 2020
Association of immune checkpoint inhibitors with respiratory infections: A reviewRyosuke Hamashima, Junji Uchino, Yoshie Morimoto, et al.
International Journal of Cancer|April 28, 2006
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomasYasuo Adachi, Chieko Aoki, Naoko Yoshio-Hoshino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancerNaoko Inoshima, Yoichi Nakanishi, Takahiro Minami, et al.
Translational Lung Cancer Research|February 4, 2020
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)Yusuke Chihara, Tadaaki Yamada, Junji Uchino, et al.
The Journal of Organic Chemistry|February 26, 2024
Divergent Nine-Step Syntheses of Perhydrohistrionicotoxin Analogs and Their Inhibition Activity Toward Chicken α4β2-Neuronal Nicotinic Acetylcholine ReceptorsKeisuke Nishikawa, Yosuke Ono, Sumito Mori, et al.
Pageof 34